Summary
Bristol-Myers Squibb Company (BMY) reported its second quarter and first half results for 2001, demonstrating solid revenue and earnings growth. Net sales for the second quarter increased by 7% year-over-year, driven by a strong performance in pharmaceuticals, notably the Glucophage franchise and Plavix. Despite a decrease in sales for Taxol due to generic competition, the overall pharmaceutical segment showed resilience. The company is actively managing its product portfolio, evidenced by the announced sale of Clairol and the pending acquisition of DuPont Pharmaceuticals. This strategic move is expected to significantly enhance BMY's pharmaceutical pipeline and market position.
Key Highlights
- 1Net sales for the second quarter of 2001 increased by 7% to $4.71 billion, with pharmaceutical sales up 8% globally.
- 2The Glucophage franchise showed robust growth, with total sales increasing by 57% to $763 million.
- 3Plavix, a key cardiovascular drug, saw a significant 43% increase in sales to $317 million.
- 4Sales of Taxol declined by 21% to $325 million due to generic competition in the U.S. market.
- 5The company announced an agreement to sell its Clairol beauty care business to Procter & Gamble for $4.95 billion.
- 6Bristol-Myers Squibb is acquiring DuPont Pharmaceuticals for $7.8 billion, a significant strategic move to bolster its pharmaceutical offerings.
- 7Net earnings increased by 10% for the quarter to $1.102 billion, with diluted EPS rising to $0.56.
Frequently Asked Questions
Bristol-Myers Squibb is actively managing its portfolio through strategic acquisitions and divestitures. The company announced the sale of its Clairol business and is in the process of acquiring DuPont Pharmaceuticals. These actions indicate a focus on strengthening its core pharmaceutical operations and pipeline.
Generic competition is impacting some of BMY's established products. Notably, Taxol sales decreased by 21% in the U.S. due to generic alternatives. Similarly, Buspar sales saw a significant decline. The company is mitigating these impacts through growth in newer products and strategic R&D.
Key growth drivers include the strong performance of the Glucophage franchise (including new formulations like Glucovance and Glucophage XR), continued growth for cardiovascular drugs like Plavix and Avapro, and increasing sales of Videx EC and Tequin. The planned acquisition of DuPont Pharmaceuticals is also expected to be a significant future growth driver.
The company has classified the Clairol and Zimmer businesses as discontinued operations. For the second quarter of 2001, net earnings from discontinued operations were $99 million. Zimmer was spun off to stockholders in August 2001, and the sale of Clairol to Procter & Gamble is pending.